Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY6-F9
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intraperitoneal (preclinical)
01
Overview
HY6-F9 is a monoclonal antibody developed specifically to counteract fentanyl and its analogues. This antibody binds fentanyl in serum, thereby reducing its distribution to the brain and other organs and reversing fentanyl-induced toxicity such as antinociception, respiratory depression, and bradycardia. It is able to sequester fentanyl and its metabolite norfentanyl in serum, reducing brain concentrations of fentanyl and offering prophylactic as well as therapeutic interventions for opioid overdose. HY6-F9 has been shown to be effective in animal models and works by high-affinity binding to the drug. It can be used alone or in combination with the opioid antagonist naloxone to reverse or prevent effects of fentanyl. Structural studies have elucidated the antibody's binding to fentanyl and supported the rational engineering of improved mAbs in this class[2][4][6].
- Other names
- anti-fentanyl monoclonal antibody HY6-F9
Beyond the preview
Go deeper on HY6-F9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HY6-F9.